Heterocyclic compound and application thereof and pharmaceutical composition containing heterocyclic compound

A technology of heterocyclic compounds and pharmacy, applied in the direction of active ingredients of heterocyclic compounds, drug combinations, antipyretics, etc., can solve the problem of single structure of ATX inhibitors

Active Publication Date: 2019-08-23
SUZHOU SINOVENT PHARMA CO LTD
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is that the existing ATX inhibitors have relatively simple structures and o

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterocyclic compound and application thereof and pharmaceutical composition containing heterocyclic compound
  • Heterocyclic compound and application thereof and pharmaceutical composition containing heterocyclic compound
  • Heterocyclic compound and application thereof and pharmaceutical composition containing heterocyclic compound

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0824] Preparation Example 1 Intermediate synthesis method

[0825]

[0826] Step 1, 2-Amino-4-(3,4-difluorophenyl)thiazole-5-carbonitrile

[0827] To a solution (18 mL) of 3-(3,4-difluorophenyl)-3-oxopropionitrile (1.38 g, 7.63 mmol) in ethanol was added pyridine (0.60 g, 7.63 mmol). The reaction solution was stirred at 70°C for 15 minutes and then cooled to room temperature. Mix thiourea (1.18 g, 215.52 mmol) and iodine (1.96 g, 7.63 mmol) in ethanol (18 mL). This mixture was slowly added dropwise to the above solution and stirred at room temperature for 1 hour. The reaction was quenched by adding cold sodium thiosulfate solution (10 mL) to the reaction solution. Filter and wash the filter cake with water. After the filter cake is dried, 2-amino-4-(3,4-fluorophenyl)thiazole-5-carbonitrile is obtained as an off-white solid (1.50 g, 82.9%). 1H NMR(400MHz,DMSO-d6)δ8.28(s,2H),,7.89–7.83(m,1H),7.82–7.78(m,1H),7.65-7.58(m,1H)

[0828] Step 2. 2-Chloro-4-(3,4-difluorophenyl)thiazole-5...

Example Embodiment

[0845] Example 1S-0021: 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazine-1- Yl)imidazo[1,2-a]pyrimidin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile

[0846]

[0847] Step 1: 2-Chloro-1-(3-hydroxyazetidin-1-yl)acetyl

[0848] To an aqueous solution (8 mL) of potassium carbonate (3 g, 22 mmol) was added 3-hydroxyazetidine hydrochloride (1.1 g, 10 mmol). The reaction solution was stirred at room temperature for 10 minutes, and then diluted with dichloromethane (8 mL) and the reaction solution was cooled to 0°C, and then 2-chloroacetyl chloride (1.3 g, 12 mmol) was slowly added dropwise. The reaction solution was stirred at room temperature for 2 hours, filtered, and the organic phase was separated. The aqueous phase was extracted with a methanol / ethyl acetate mixture (1 / 1) (20 mL x 6). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was resuspended in acetone (50 mL) and stirred vigorou...

Example Embodiment

[0867] Example 2S-0022: 2-((2-ethyl-5-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazine-1- Yl)-7-methyl-2H-indazol-3-yl)(methyl)amine)-4-(4-fluorophenyl)thiazole-5-carbonitrile

[0868]

[0869] Step 1: 5-Bromo-2-fluoro-3-methylbenzonitrile

[0870] Iodine (11.67g, 46.3mmol) was added to the mixture of 5-bromo-2-fluoro-3-methylbenzaldehyde (5g, 23.1mmol) in tetrahydrofuran (20mL) and ammonia (20mL), and the reaction solution was kept at room temperature. Stir for 16 hours. The reaction was quenched by adding sodium bisulfite solution (20 mL) to the reaction solution, and then extracted with ethyl acetate (50×2 mL). The organic phases were combined, washed with saturated brine (10mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated to obtain 5-bromo-2-fluoro-3-methylbenzonitrile as a white solid (5g, 98%) , Directly used in the next reaction without purification. 1 H NMR(400MHz, CDCl 3 )δ7.55-7.59 (m, 2H), 2.32 (s, 3H).

[0871] Step 2: 5-bromo-2-ethyl-7-meth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a heterocyclic compound and application thereof and a pharmaceutical composition containing the heterocyclic compound. The invention provides a heterocyclic compound shown in formula I or a pharmaceutically acceptable salt thereof. The compound has novel structure and better ATX inhibitory activity.

Description

technical field [0001] The invention provides a heterocyclic compound, its application and a pharmaceutical composition containing it. Background technique [0002] Autotaxin (ATX, also known as ENPP2 [external nucleotide pyrophosphatase / phosphodiesterase 2] or lysophospholipase D) is an enzyme that converts lysophosphatidylcholine (LPC) into the biologically active phospholipid derivative lysophospholipid Acid (LPA) secreted lysophospholipase D (lysoPLD). LPA and through specific G protein-coupled receptors (LPA 1-6 ) signal to exert its biological activity. Since the ATX / LPA axis is involved in many physiological and pathophysiological processes, it has attracted considerable interest from the pharmaceutical industry. LPA and LPA receptors are involved in many diseases such as fibrotic diseases (such as idiopathic pulmonary fibrosis, IPF), proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D417/14C07D401/14C07D403/14C07D471/04C07D487/04C07D491/048A61K31/496A61K31/519A61K31/5025A61K31/53A61K31/506A61P1/16A61P11/00A61P35/00A61P29/00A61P19/02A61P37/02A61P9/00A61P25/28A61P17/00A61P9/14
CPCC07D417/14C07D401/14C07D403/14C07D471/04C07D487/04C07D491/048A61P1/16A61P11/00A61P35/00A61P29/00A61P19/02A61P37/02A61P9/00A61P25/28A61P17/00A61P9/14A61K31/496A61K31/519A61P37/00C07D495/04A61K45/06A61K31/4418A61K2300/00
Inventor 胡永韩吴冬冬彭薇李昕胡凡黄彬朱金莲吴予川
Owner SUZHOU SINOVENT PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products